Steroid-containing ophthalmic solutions more likely to be contaminated

Article

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free.

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free, according to a report published in the October issue of the British Journal of Ophthalmology.

Danny H-Kauffmann Jokl and colleagues from the New York Medical College, New York, USA conducted a study to assess the frequency of ophthalmic solution contamination in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria and the results were analysed according to the therapeutic class of the solution, how long the bottle was in use for and the appearance of the bottle upon visual inspection.

Ten (8%) of the solutions were contaminated with bacteria: four of eight steroid-containing anti-inflammatory solutions, two of six combination antimicrobial and steroid-containing anti-inflammatory solutions, two of 34 solutions for the treatment of glaucoma and two of 57 medications for dry eye. None of the mydriatic, miotic or non-combination antimicrobial solutions were found to be contaminated.

Just 30% of the contaminated bottles were considered "dirty" under visual inspection. Neither length of time that bottles had been in use or appearance of the bottles were found to be predictors of contamination.

The frequent contamination during reuse of certain steroid-containing ophthalmic solutions has led the research team to suggest that single-use solutions may be preferable.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.